Open AccessEfficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial
Author(s) -
Jinghui Lin,
Meifang Li,
Shijie Chen,
Lihong Weng,
He Zhou
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s313056
Subject(s) - medicine , pemetrexed , carboplatin , t790m , lung cancer , oncology , clinical endpoint , gefitinib , chemotherapy , single center , brain metastasis , progression free survival , progressive disease , epidermal growth factor receptor , cancer , metastasis , clinical trial , cisplatin
This single-center, open-label, single-arm, phase II clinical trial aimed to examine the efficacy and safety of the first-generation EGFR-TKIs combined with chemotherapy among treatment-naïve advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations.